Mark Litzow
Hematology · Rochester, MNNPI 1871579672
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $62,761 of the $98,876 with a category attached, or 63.5%. Amgen accounts for 76.3% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $40,531, more than ten times the $65 reported in 2019. Among hematology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $2996.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$75K
- Beigene (suzhou) Co., Ltd.$17K
- Jazz Pharmaceuticals Inc.$3K
- E.r. Squibb & Sons, L.L.C.$2K
- Gilead$1K
- AstraZeneca$446
- plus $344 from 4 others
Across 50 payments — averaging $138,924 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$5.8M
- Servier Affaires Medicales$840K
- AbbVie$244K
- Astellas Pharma Global Development$69K
- Novartis$2K
- Boehringer Ingelheim International GmbH$210
What the payments were for
- Consulting fees$35,36136%
- Speaking & faculty fees$62,76163%
- Travel & lodging$2890%
- Food & beverage$3960%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 20 | $75,487 |
| Beigene (suzhou) Co., Ltd. | 1 | $16,575 |
| Jazz Pharmaceuticals Inc. | 1 | $3,200 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,547 |
| Gilead | 2 | $1,276 |
| AstraZeneca | 4 | $446 |
| National Marrow Donor Program | 1 | $189 |
| Bristol Myers Squibb | 1 | $65 |
| Medexus Pharma, Inc. | 1 | $47 |
| Servier Pharmaceuticals LLC | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,876 in reported general payments places this provider in the 90th percentile of 111 hematology providers in Minnesota.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 15 | $249,533 |
| EliquisApixaban | 14 | $7,865 |
| Imatinib Mesylate | 12 | $1,642 |
| Penicillin V Potassium | 37 | $651 |
| Hydroxyurea | 19 | $399 |
| Acyclovir | 16 | $256 |
| Rosuvastatin Calcium | 24 | $213 |
| Gabapentin | 15 | $194 |
| Metoprolol Succinate | 14 | $142 |
| Allopurinol | 15 | $119 |
| Carvedilol | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Other hematology in Rochester
- Shaji KumarRochester$452K
- Yi LinRochester$365K
- David DingliRochester$299K
- Morie GertzRochester$261K
- Grzegorz NowakowskiRochester$235K
- Sameer ParikhRochester$151K
- Lindsey RoekerRochester$106K
- Angela DispenzieriRochester$87K
- Prashant KapoorRochester$71K
- Thomas WitzigRochester$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.